Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Aims to become India’s leading cancer testing company
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
Subscribe To Our Newsletter & Stay Updated
